psychopharmacology of anxiety: part ii ocd & ptsd
DESCRIPTION
This PPT is part 2 of 2 lectures given to second year pharmacy students in a pharmacology & toxicology class.TRANSCRIPT
![Page 1: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/1.jpg)
Anxiety II: Agents for PTSD & OCD
Brian J. Piper, Ph.D., [email protected]
Office Hours: T/Th 3-4 or by appointment
February 1, 2013
![Page 2: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/2.jpg)
Objectives
• Pharmacy students should be able to:– List the key characteristics of Post-Traumatic Stress
Disorder & Obsessive Compulsive Disorder– Rank the therapeutic options by efficacy and
differentiate the pharmacotherapies by MOA and adverse events.
![Page 3: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/3.jpg)
Psychotherapy & Anxiety Disorders
Anxiety Disorder Importance of PsychotherapyPhobias Systematic desensitization is gold standard.
Social Anxiety Disorder >50% of patients show response to CBTD
GAD CBT and pharmacotherapy have similar efficacyD
Panic Disorder CBT produces improvements in 75% of patientsD
Obsessive Compulsive Dis CBT (with or without SSRI) is recommended as first-line txD
Post-Traumatic Stress Dis EMDR > fluoxetine in maintaining improvementsD
• Specific therapies, typically brief ( < 12 weeks) have solid empirical support
• Effects are delayed but sustained• Important option for vulnerable populations
DDiPiro et al. (2012). Pharmacotherapy: A Pathophysiologic Approach, Chapters 79 & 80.
![Page 4: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/4.jpg)
Obsessive Compulsive Disorder
Example Patient #1 (0 to 2:50): http://www.youtube.com/watch?v=tPFQMRx2l3Y
-------
--------
---------------
![Page 5: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/5.jpg)
Common Obsessions
1) Dirty 2) Aggression 3) Religion 4) Sex
![Page 6: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/6.jpg)
Famous OCD Cases
![Page 7: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/7.jpg)
Yale Brown Obsessive Compulsive Scale
• Obsessions (5 items)– How much of your time do you occupy with
obsessions? None ------ Extreme (8+ hours/day)– How much do your obsession interfere socially or with
work? Not at all ----- Extreme (Incapacitating)• Compulsions (5 items)– How much time do you spend performing compulsive
behaviors? None ---- 8+ hours/day– How much control do you have over the rituals?
Complete Control ---- No control, unable to even delay
7To take test: http://www.psymed.info/psymed/default.aspx?m=Test&id=52&l=3
![Page 8: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/8.jpg)
OCD Options
2nd Line
1st Line
Modified from Stahl, S. (2008). Essential Psychopharmacology, p. 770.
![Page 9: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/9.jpg)
Fluvoxamine
• MOA: SRI• Indications: FDA approved for OCD (adult & pediatric)• Half-Life: 16 hours• Adverse Effects: nausea, vomiting, weight gain, sexual
--------------------------- ------------------------------
![Page 10: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/10.jpg)
Paradoxical Aggression?• Animal studies demonstrate inverse
relationship between 5-HT & aggression• E.H. receives sertraline, later fluvoxamine• Parents of E.H. sue Solvay• Solvay withdraws fluvoxamine (2002 – 2008)• Aggressive patients -> drug
Drug -> Aggression
http://www.denverpost.com/golf/ci_5094436 1981 - 1999
![Page 11: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/11.jpg)
OCD: SSRI, CBT, or Both?
Baseline Week 8 (Change) Week 16 (Change)
Control (Wait List) 26.8 26.4 (-0.4) NA
CBT (1-16) 25.3 21.5 (-3.8)* 13.5 (11.8)*
FLVX (1-16) + CBT (9-16) 27.2 20.8 (-6.4)* 15.6 (11.6)*
• OCD patients randomized to Cognitive Behavior Therapy (CBT), CBT & Fluvoxamine (50-300, Mean = 235 mg/day), or a wait-list.
• Clinicians completed the Yale-Brown Obsessive Compulsive Scale (0 – 40) – normal = 0-7– mild = 8-15; moderate = 16 -23 – 24-31 = severe– 32-40 = extreme
*p < .01 versus Baseline
Von Balkom et al. (1998). Journal of Nervous & Mental Disease, 186(8), 492-499.
![Page 12: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/12.jpg)
5 Year Follow-Up
CBT (N = 32) CBT + Fluvoxamine (N = 39)
Current YBOCS (SD) 12.3 (8.9) 14.9 (9.1)
YBOCS Improved by >7 78.1% 73.7%
Additional CBT 53% 72%
Using Anti-depressants 19% 51%*
No Longer OCD 62.5% 51.3%
*p < .005
van Oppen et al. (2005). J of Clinical Psychiatry, 66, 1415-1422.
![Page 13: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/13.jpg)
Early OCD Age of Onset
General description (Skip Ad, 0 to 2:25): http://www.youtube.com/watch?v=izT40QNFXuMDelorme et al. (2005). Psychological Medicine, 35(2), 237-243.
Early Onset(N = 141)
Late-onset (N = 20)
MDD 36.2% 66.6%*
ADHD 31.2% 25.0%
Tourette’s 26.9% 0.0%*
GAD 11.3% 41.2%*
* p < .01
![Page 14: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/14.jpg)
Fluvoxamine & Age• Max dose – Adults: 300 mg/day– Adolescents: 300 mg/day– Children: 200 mg/day
• Efficacy: similar across age• Contraindications: MAO-Is• Other: CYP1A2• Adverse Effects: similar across age, transient
gastrointestinalCheer & Figgitt (2002). CNS Drugs, 16(2), 139-144.http://www.pdr.net/drugpages/concisemonograph.aspx?concise=1452
![Page 15: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/15.jpg)
SRIs & Adolescence• The 5-HT system undergoes dynamic changes during adolescence• Does chronic anti-depressant treatment alter neurobehavioral development?• Oral paroxetine (15 mg/kg), but not fluvoxamine (30 mg/kg), from PD 33-62
temporarily, reduced weight.
Jong et al (2006). European Neuropsychopharmacology, 16, 39-48.
![Page 16: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/16.jpg)
SRIs & Adolescence• The 5-HT system undergoes dynamic changes during adolescence• Does chronic anti-depressant treatment alter neurobehavioral development?• After a 23 day drug free period, the rats were tested on the elevated plus maze
V P F
Jong et al (2006). European Neuropsychopharmacology, 16, 39-48.
![Page 17: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/17.jpg)
Common Sexual Effects• Sexual dysfunction (SD) is common among
patients with anxiety & depression• Drug-induced SD is under-reported unless
patients queried directly• SD = ↓ desire, ↓ arousal, ↓ orgasm
SertralineVenlafaxineCitalopramParoxetineFluoxetineImipraminePhenelzineDuloxetineEscitalopramFluvoamine
Serretti et al. (2009). Journal of Clinical Psychopharmacology, 29, 259 – 266.
![Page 18: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/18.jpg)
Males > Females
Serretti et al. (2009). Journal of Clinical Psychopharmacology, 29, 259 – 266.
![Page 19: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/19.jpg)
Post Traumatic Stress Disorder
• A) Exposure to actual or threatened death, serious injury, or sexual violation
• B) Intrusion symptom(s): – spontaneous or cued memories– dreams– flashbacks
• C) Avoidance of stimuli associated with traumatic event
• D) Social or occupational impairmentExample (1st 3 min): http://www.youtube.com/watch?v=7aFs6695VyQSummarized from: http://www.dsm5.org/ProposedRevision/Pages/proposedrevision.aspx?rid=165
![Page 20: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/20.jpg)
Neural Substrate of PTSD?
Stahl et al. (2008). Essential Psychopharmacology, p. 748.
SSRIs increase 5-HT but therapeuticlag
SSRIs increases Brain Derived Neurotrophic Factor (BDNF)
BDNF increases neurogenesis
![Page 21: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/21.jpg)
PTSD & Reduced Hippocampal Volume
Karl et al. (2006). Neuroscience & Biobehavioral Reviews, 30, 104-131.
![Page 22: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/22.jpg)
PTSD Options (DiPiro/Stahl)
Modified from Stahl, S. (2008). Essential Psychopharmacology, p. 770.
*FDA Approvedsertralineparoxetine
*
![Page 23: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/23.jpg)
PTSD Treatment HierarchyDepartment of Defense/Veterans Affairs 2010
• “Psychotherapy is the preferred treatment option.”
• 1st Line Pharmacotherapies: SSRI, SNRI• Not Recommended: Benzos & anti-psychotics
as mono-therapy or used adjunctively
Jeffreys et al. (2012). Journal of Rehabilitation Research & Development, 49(5), 703-715.
![Page 24: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/24.jpg)
Rationale For Avoiding Benzos with PTSDThe veteran was diagnosed with PTSD and panic disorder by a psychiatrist in the PTSD Clinic. He was started on sertraline and after several months at a dose of 200 mg daily, he reported only modest reductions in PTSD symptoms. The panic disorder improved but he continued to take clonazepam 1 mg 1–3 times per week to prevent panic attacks when leaving his home. He was referred for PE (Prolonged Exposure) therapy. Although the PE went well in the initial weeks, both the patient and his therapist noted that he was relatively unaffected by anxiety in some therapy sessions. A careful review of his medication use found he was taking clonazepam prior to driving from his home to the VA medical center because driving alone was a common trigger for panic attacks. He was encouraged to not use clonazepam within 24 hours of a PE session, and after several more weeks, he completed PE without difficulty. The post-PE score on the PCL was below the cutoff for PTSD diagnosis.
Jeffreys et al. (2012). Journal of Rehabilitation Research & Development, 49(5), 703-715.
![Page 25: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/25.jpg)
Summary
• Anxiety Disorders are complex psychiatric conditions that require multi-disciplinary treatment.
• SSRIs are first-line pharmacotherapies for OCD & PTSD although there are substantial differences among members of this class.
![Page 26: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/26.jpg)
Cingulate Cortex
26
![Page 27: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/27.jpg)
Anterior Cingulate & OCD
• OCD and controls completed a difficult continuous performance test during fMRI.
• OCD > controls in Anterior Cingulate Cortex
Ursu et al. (2003). Psychological Science, 14, 347-353.
![Page 28: Psychopharmacology of Anxiety: Part II OCD & PTSD](https://reader033.vdocuments.net/reader033/viewer/2022061112/5456e4b1af7959160a8b7672/html5/thumbnails/28.jpg)
More OCD Patients
• 1st Two Minutes: http://www.youtube.com/watch?v=44DCWslbsNM
• Or: http://www.youtube.com/watch?v=Rn1OYlYzgm8
28